Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

As part of Y Combinator’s push into computational biology and bioinformatics, the early-stage firm is backing a team that used to work on the Human Genome Project and is now experimenting with RNA ...

Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President ST. LOUIS, January 08, 2025--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage ...

In living organisms, there are many chemical reactions taking place. These reactions have many different functions, including breaking down the food we eat and getting energy from the broken down food ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...

Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC ...

Cofactor Genomics has announced an $18 million Series A financing round led by Menlo Ventures, with participation from DCVC, Ascension Ventures, iSelect, Y Combinator, Wilson Sonsini Goodrich & Rosati ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Cofactor AI has created software that uses artificial ...

Cofactor AI, a company that helps hospitals appeal claims denials, announced it raised $4 million in a seed funding round led by Drive Capital. Cofactor AI’s platform, Cofactor Denial Suite, combines ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been ...